Home › Compound Library › Paliperidone (Invega)

Paliperidone (Invega)

Antipsychoticprescriptionoral · inferred

Atypical antipsychotic D2/5-HT2A antagonist; it is the 9-hydroxy active metabolite of risperidone. Available as oral ER tablets (OROS) 3-12 mg QD and as long-acting injectables (palmitate monthly, three-monthly, and six-monthly). Plasma half-life ~23h for oral ER. Oral bioavailability ~28%. Minimal CYP metabolism, predominantly renally excreted (~59% unchanged), fewer CYP drug interactions than risperidone. Hyperprolactinemia and orthostatic hypotension are prominent AEs.

Projected serum levels — 6 mg, once daily

Paliperidone (Invega)
Paliperidone (Invega) modeled serum levels, 6 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 4
Paliperidone (Invega) modeled serum levels with a loading dose of 18 mg, then 6 mg once daily The first dose is larger so levels approach steady state faster. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 6 mg once daily (oral).

Loading schedule: 18 mg on day 1, then 6 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~4 days: peak ≈ 1.4 mg, trough ≈ 1.3 mg body load. Population-based estimate over 15 days for a 6 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antipsychotic
Route modeled
Oral
Model confidence
inferred
Half-life
23 h
Common dose
6 mg
Suggested maximum
12 mg/day
Reference dose range
3–12 mg (single dose)
Suggested cadence
once daily
Validated against
6 mg oral — Cmax 0.009 mg/L at 24 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Paliperidone (Invega) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Paliperidone (Invega) Serotonin risk

    25I-NBOMe and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Paliperidone (Invega) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Paliperidone (Invega) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Paliperidone (Invega) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Paliperidone (Invega) Serotonin risk

    4-AcO-DMT (Psilacetin) and Paliperidone (Invega) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 198 modeled interaction pairings for paliperidone (invega) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics of paliperidone, paliperidone palmitate, and risperidone Samtani MN et al. · Clinical Pharmacokinetics, 2009 DOI

    Comprehensive PK comparison of oral paliperidone, paliperidone palmitate LAI, and risperidone; establishes ~23h oral ER half-life and renal elimination profile.

  2. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia Kramer M et al. · Journal of Clinical Psychopharmacology, 2007 DOI

    Pivotal phase 3 trial establishing paliperidone ER 3-15 mg QD efficacy for preventing schizophrenia symptom recurrence.

2 published studies referenced in the app, each with a plain-language summary.